Pemvidutide Real Results: Weight Loss Timeline & What Patients Report

Introduction

Pemvidutide’s main efficacy dataset is the MOMENTUM phase 2 trial: 391 adults with obesity (mean BMI 37) followed for 48 weeks across three doses (1.2, 1.8, 2.4 mg) plus placebo. Top-line results published in 2024 showed mean weight loss of 10.3%, 11.2%, and 15.6% at the three doses versus 2.2% on placebo.

This article walks through what those numbers mean week by week, where weight loss happens fastest, what fat versus lean mass loss looks like, and where pemvidutide sits versus semaglutide and tirzepatide.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

When Does Pemvidutide Weight Loss Start?

Most patients in MOMENTUM lost about 2 to 3% of baseline weight by week 4 and 5 to 6% by week 8. Appetite suppression starts within the first 3 to 7 days after the first dose, and water/glycogen losses account for some of the early drop before fat oxidation catches up.

Quick Answer: MOMENTUM week 48: 15.6% mean weight loss at 2.4 mg vs 2.2% on placebo

Visible body composition changes usually take 6 to 12 weeks. Patients report noticing tighter fitting clothes around week 8 to 10 and clearer changes in body shape by week 16. The drug doesn’t drop weight overnight.

People comparing pemvidutide to semaglutide and tirzepatide typically see similar starting trajectories. The first 4 to 8 weeks of weight loss is dominated by appetite suppression effects, which are present across the GLP-1 class.

What Does the Weight Loss Curve Look Like Over 48 Weeks?

MOMENTUM weight loss trajectories at 2.4 mg showed a roughly linear decline through about week 32, then a slowing-but-not-flat curve from weeks 32 to 48. At endpoint, mean loss was 15.6%, and the curve was still trending downward.

Compare that to semaglutide in STEP 1 (Wilding et al. 2021 NEJM): mean weight loss of 14.9% at 68 weeks, with the curve plateauing around weeks 52 to 60. Pemvidutide may eventually hit a similar or higher ceiling once phase 3 runs longer trials.

The dose-response was clear: 1.2 mg produced 10.3%, 1.8 mg produced 11.2%, and 2.4 mg produced 15.6%. The jump from 1.8 to 2.4 is larger than from 1.2 to 1.8, which is consistent with how GLP-1 dose-response often looks at higher levels.

How Much Fat vs Lean Mass Is Lost?

DEXA scans from a MOMENTUM subset showed roughly 78% of total weight lost was fat mass and 22% was lean mass at the 2.4 mg dose. That ratio is favorable compared to typical GLP-1 trials where 25 to 40% of weight loss can come from lean tissue.

The proposed mechanism is glucagon’s protein-sparing effect during caloric deficit. Glucagon activates fatty-acid oxidation in the liver and muscle and shifts energy substrate use away from amino acids when food intake drops.

That said, sample sizes for DEXA were small, and phase 3 will need to confirm. Patients who layer resistance training onto pemvidutide therapy probably do best for preserving lean mass regardless of which GLP-1-class drug they’re on.

What About Waist Circumference and Visceral Fat?

MOMENTUM showed reductions in waist circumference proportional to weight loss, with mean drops of around 9 to 11 cm at the 2.4 mg dose. Visceral fat (the deep abdominal fat associated with cardiometabolic disease) typically drops faster than subcutaneous fat with GLP-1 therapy, and pemvidutide should follow that pattern.

Liver fat reduction (covered below) is the most striking imaging finding. Skeletal muscle imaging hasn’t been reported in detail from phase 2.

How Does Pemvidutide Affect Liver Fat?

The IMPACT MASH phase 2b trial showed MRI-PDFF liver fat reductions of 57.1% at 1.2 mg, 58.5% at 1.8 mg, and similar magnitude at 2.4 mg at 24 weeks. MASH resolution without worsening fibrosis was achieved in 59.1% of 1.2 mg patients versus 19.1% on placebo.

These are large effects on liver fat compared to pure GLP-1 drugs at similar timepoints. Semaglutide’s ESSENCE phase 3 (top-line 2024) showed MASH resolution rates of about 63% at 72 weeks at 2.4 mg, which is similar but at 3x the trial duration.

Pemvidutide’s glucagon receptor activity drives hepatic fatty acid oxidation directly, which is why liver-fat reductions are larger and faster than they would be from caloric restriction alone.

What Is the Typical Month-by-month Pattern?

Month 1 (weeks 1 to 4): Starting dose 1.2 mg. Appetite suppression kicks in within days. Mild to moderate GI side effects, especially nausea, for the first 1 to 2 weeks. Mean weight loss about 2 to 3%.

Month 2 (weeks 5 to 8): Dose increases to 1.8 mg at week 5. Brief return of mild side effects. Mean cumulative weight loss about 5 to 6%. Clothes start fitting differently.

Month 3 (weeks 9 to 12): Dose increases to 2.4 mg at week 9. Another mild flare of side effects, then re-adaptation. Mean cumulative weight loss about 7 to 9%.

Month 4 to 6 (weeks 13 to 24): Steady weight loss continues at 2 to 3% per month. Cumulative loss reaches 11 to 13%.

Month 7 to 12 (weeks 25 to 48): Weight loss slows but continues. Cumulative loss reaches 15.6% on average at 2.4 mg in MOMENTUM.

Do All Patients Respond the Same Way?

No. Individual variation is large. In MOMENTUM, roughly 22% of patients on 2.4 mg lost 20% or more of baseline weight, while a smaller fraction (perhaps 10 to 15%) had limited response (under 5% loss). This response heterogeneity matches what’s seen with semaglutide and tirzepatide.

Predictors of strong response include adherence to the weekly schedule, dietary changes that complement appetite suppression, regular activity, and the absence of strong counter-regulatory factors like high stress, poor sleep, or certain medications (atypical antipsychotics, insulin, some antidepressants).

Patients can usually tell within the first 8 to 12 weeks whether they’re a strong responder. A clinician can decide whether to continue, adjust dose, or consider switching agents based on that early signal.

How Does Pemvidutide Compare to Semaglutide for Weight Loss?

STEP 1 semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks. MOMENTUM pemvidutide 2.4 mg produced 15.6% at 48 weeks. The pemvidutide curve hadn’t plateaued, so longer trials would likely show more loss.

Differences favoring pemvidutide: less lean mass loss in phase 2 DEXA data, larger and faster liver fat reductions.

Differences favoring semaglutide: better cardiovascular outcomes data (SELECT, Lincoff et al. 2023 NEJM), kidney outcomes data (FLOW, Perkovic et al. 2024 NEJM), longer real-world track record, and FDA approval allowing actual access.

How Does Pemvidutide Compare to Tirzepatide?

SURMOUNT-1 tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks. Pemvidutide 2.4 mg produced 15.6% at 48 weeks. Tirzepatide currently has the edge on raw weight loss magnitude.

Tirzepatide also lowers HbA1c significantly, while pemvidutide doesn’t. For patients with type 2 diabetes, tirzepatide is the clearer choice.

For patients with significant MASH or fatty liver, pemvidutide may emerge as a preferred option once approved because of its strong liver fat effects. Patients without diabetes who don’t have MASH should probably default to tirzepatide for raw weight loss potential, semaglutide for established cardiovascular benefit, or consider retatrutide if available (phase 3 ongoing).

What Can Patients Expect After Stopping Pemvidutide?

After stopping any GLP-1 drug, weight regain is common. The STEP 1 extension (Wilding 2022 Diabetes Obesity Metab) showed about two-thirds of semaglutide weight loss returned within one year of discontinuation. Pemvidutide is likely similar because the underlying biology of returning hunger and slowed metabolic rate applies across the class.

Long-term maintenance probably requires continued therapy for most patients. That’s a major reason TrimRx and similar telehealth platforms emphasize the chronic-disease framing of obesity treatment rather than the time-limited weight loss framing.

Key Takeaway: About 21.9% of total weight lost was lean mass at 2.4 mg (lower than pure GLP-1 drugs)

How Long Should I Plan to Be on Pemvidutide?

Pemvidutide isn’t FDA-approved yet, so there’s no official duration recommendation. The class as a whole is increasingly viewed as long-term therapy, similar to medications for hypertension or hyperlipidemia.

Some patients may use pemvidutide for a defined period (12 to 24 months) to achieve weight loss, then transition to maintenance with another agent or lifestyle changes. Others may need indefinite treatment. The decision is individualized based on weight history, comorbidities, and response.

What Does TrimRx Offer in the Meantime?

Pemvidutide isn’t available outside clinical trials. TrimRx offers compounded semaglutide and tirzepatide through telehealth visits and a free assessment quiz that matches patients to the right medication based on goals, side effect tolerance, and metabolic profile.

When pemvidutide receives FDA approval (likely 2027 to 2028 at earliest), TrimRx will evaluate carrying it under standard medical oversight. Until then, the practical choice is semaglutide or tirzepatide for patients seeking GLP-1-based weight loss.

How Do Liver Enzymes and Metabolic Markers Change?

For MASH patients in IMPACT MASH, ALT dropped substantially over 24 weeks (typically 30 to 50%). Triglycerides typically fell by 20 to 30%. Fasting insulin improved.

In non-MASH MOMENTUM patients, lipid and metabolic improvements were proportional to weight loss. LDL rose modestly at higher doses (7 to 10% at 2.4 mg), which is a glucagon-related signal worth monitoring.

What About Blood Pressure Trends?

MOMENTUM showed mean systolic BP reductions of 3 to 4 mmHg at the 2.4 mg dose, with similar diastolic reductions. The effect is partly weight-loss driven and partly GLP-1-specific vascular effects.

Patients on antihypertensives may need dose reductions over time. Orthostatic symptoms can occur during periods of reduced food and fluid intake.

How Does Response Correlate with Adherence?

Trial adherence in MOMENTUM was high (around 90% completion). Real-world adherence is typically lower. Patients who miss doses or stop and restart see less consistent weight loss than those who maintain regular weekly dosing.

A practical rule: at least 80% of weekly doses on schedule for 12 months should be the goal for optimal results.

What Does the Responder Profile Look Like?

In MOMENTUM, about 22% of 2.4 mg patients lost over 20% of baseline weight. About 50% lost 10 to 20%. About 18% lost 5 to 10%. About 10% lost less than 5%.

Strong responder characteristics often include lower baseline BMI (not extreme obesity), absence of major counter-regulatory medications, consistent adherence, and concurrent lifestyle changes.

Patients can usually tell within 8 to 12 weeks whether they’re a strong, moderate, or low responder.

How Do Results Compare Across Patient Subgroups?

Phase 2 trial data didn’t show dramatic differences by sex, race, or age subgroups, but the sample size was too small for strong subgroup analysis. Phase 3 trials will provide more granular data.

Patients with significant baseline liver fat may see more dramatic improvements in liver-related markers compared to patients with normal liver fat. Weight loss is similar across these groups.

What Happens During Weight Loss Plateaus?

Most patients see weight loss slow after 6 to 9 months. True plateaus (no weight change for 4+ weeks at maintenance dose) may occur as the body adapts metabolically to lower weight.

Options at plateau: continue current treatment (some patients break through with patience), increase activity, refine diet, or consider switching to a different GLP-1 drug. There’s no consensus best approach.

How Does the TrimRx Personalized Treatment Plan Integrate Trial Data?

The TrimRx free assessment quiz and clinical evaluation account for expected response based on patient characteristics. For 2026, the personalized plan focuses on compounded semaglutide and tirzepatide because pemvidutide isn’t available.

When pemvidutide is approved and added to the TrimRx options, the personalized plan will incorporate it based on patient profile (especially MASH status and lean mass preservation priorities).

Bottom line: Direct head-to-head trials vs semaglutide or tirzepatide don’t exist yet

FAQ

How Fast Do Pemvidutide Results Show Up?

Weight loss usually begins within the first 2 weeks, accelerates through months 2 to 4, and continues through month 12 in trial data.

What’s the Maximum Weight Loss Seen with Pemvidutide?

About 22% of patients on the 2.4 mg dose in MOMENTUM lost 20% or more of baseline weight. Individual maximum results were higher than 25% in some cases.

Does Pemvidutide Work Without Diet Changes?

The drug suppresses appetite, which naturally reduces calorie intake. Patients who also make dietary changes and increase activity lose more weight than those who rely on the drug alone.

Will I Plateau on Pemvidutide?

Most patients see weight loss slow after 6 to 9 months. Whether a true plateau occurs depends on dose, individual response, and behavior changes.

How Do MOMENTUM Results Compare to Real-world Expectations?

Trial participants often have more support and structure than real-world patients, so average results in clinical practice tend to be 70 to 80% of trial averages.

Can I Expect 20% Weight Loss on Pemvidutide?

Average loss at 2.4 mg was 15.6%, with about 22% of patients hitting 20% or more. Individual results vary significantly.

Will Pemvidutide Help with Non-weight Goals?

Yes, particularly liver health (MASH resolution in 59% of phase 2 patients) and possibly cardiovascular and metabolic risk markers. Direct CV outcomes data isn’t available yet.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.